Efficacy and tolerability of nabumetone in the treatment of osteoarthritis of the knee joint: an open trial.
Nabumetone is the first of a new alkalone class of non-steroidal anti-inflammatory drugs with a lower propensity for gastric irritation than either aspirin or indomethacin. The efficacy and tolerability of nabumetone was studied in 75 patients suffering from acute or chronic osteoarthritis of the knee joint. The efficacy of treatment with 1 g nabumetone daily for 8 weeks was very good. Both swelling and effusion were completely resolved in all patients at the end of 4 weeks. Improvements in functional capacity, restriction of movement and pain were seen in 43-73% of patients at week 2 and in 72-92% at week 4. The overall response was subjectively assessed at week 8 as excellent or good in 83% of cases both by the patients and by the investigators. Nabumetone was particularly well tolerated; no adverse events or changes in laboratory values were reported.